

Supplementary material

Systematic review and meta-analysis of new generation of tyrosine kinase inhibitors vs. imatinib for newly diagnosed chronic myeloid leukemia

Pan Pan¹, Lijuan Wang², Yanjun Wang³, Li Shen¹, Pingping Zheng¹, Chunli Bi¹, Anning Zhang¹, Yaogai Lv¹, Zhiqiang Xue¹, Mengzi Sun¹, Chong Sun¹, Jiagen Li¹, Lina Jin^{1*}, Yan Yao^{1*}

¹ Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, School of Public Health, Jilin University, NO. 1163 Xinmin Street, Changchun, Jilin, China, 130021,

² Department of Neurology, The Neuroscience Center, The First Hospital of Jilin University, Jilin University, Changchun, China, 130021,

³ Nursing Department, the second hospital of Jilin University, Changchun, Jilin, China, 130021.

* Correspondence: jinln@jlu.edu.cn; yaoyan@jlu.edu.cn; Tel.: +86043185619451




Fig 1. Funnel plot: MMR at 12 months




Fig 2. Forest Plot of the Early Molecular Response in Patients with Chronic Myeloid Leukemia Treated with NG-TKIs vs Imatinib. The square represents point estimate, the size reflects the weight in the pooled analysis, and the horizontal bar represent the 95% CI. Diamond represent the pooled point estimate. NG-TKI, new generation of tyrosine kinase inhibitor.




Fig 3. Forest Plots of the CML-related death in Patients with Chronic Myeloid Leukemia Treated with NG-TKIs vs Imatinib. The squares represent point estimate, their sizes reflect the weight in the pooled analysis, and the horizontal bars represent the 95% CI. Diamonds represent the pooled point estimate. NG-TKI, new generation of tyrosine kinase inhibitor.




Fig 4. Forest Plots of Progression to AP/BC in Patients with Chronic Myeloid Leukemia Treated with NG-TKIs vs Imatinib. The squares represent point estimate, their sizes reflect the weight in the pooled analysis, and the horizontal bars represent the 95% CI. Diamonds represent the

pooled point estimate. NG-TKI, new generation of tyrosine kinase inhibitor.




Fig 5. Forest Plots of the PFS in Patients with Chronic Myeloid Leukemia Treated with NG-TKIs vs Imatinib. The squares represent point estimate, their sizes reflect the weight in the pooled analysis, and the horizontal bars represent the 95% CI. Diamonds represent the pooled point estimate. NG-TKI, new generation of tyrosine kinase inhibitor; PFS, progression-free survival.